

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Date Submitted: April 2, 2003 (use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	January 24, 2003
				First Name of Inventor	Naoshi Fukushima, et al.
				Group Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	065678-0108

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
LAB	A1	4,946,778	A	GENEX CORP.	08/07/1990	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
LAB	A2	WO	00/53634	A1	CHUGAI SEIYAKU KABUSHIKI KAISHA	09/14/2000		
LAB	A3	WO	99/12973	A1	CHUGAI SEIYAKU KABUSHIKI KAISHA	03/18/1999		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
LAB	A4	MATEO ET AL., "CD 47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia," <i>Nature Medicine</i> (November 1999), vol. 5, No. 11, pp. 1277-1284.		
	A5	PETTERSEN, ET AL., "CD47 signals T cell death," <i>J. Immunol.</i> (15 June 1999), Vol. 162, No. 12, pp. 7031-7040.		
	A6	ROZSNYAY ET AL., "Phenylarsine oxide (PAO) blocks antigen receptor-induced calcium response and tyrosine phosphorylation of a distinct group of proteins," <i>Immunology Lett.</i> (August 1993), Vol. 37, Nos. 2 - 3, pp. 197-205.		
	A7	BAZZONI ET AL., "Chimeric tumor necrosis factor receptors with constitutive signaling activity," <i>Proc. Natl. Acad. Sci. USA</i> (6 June 1995), Vol. 92, No. 12, pp. 5376-5580.		
	A8	GELL ET AL., "TR60 and TR80 tumor necrosis factor (TNF)-receptors can independently mediate cytolysis," <i>Lymphokine and Cytokine Research</i> (June 1993), Vol. 12, No. 3, pp. 143-148.		
	A9	O'BRIEN ET AL., "Monoclonal antibodies for the human insulin receptor stimulate intrinsic receptor-kinase activity," <i>Biochim. Soc. Trans.</i> (1986), Vol. 14, No. 6, pp. 1021-1023.		
	A10	YARDEN ET AL., "Self-phosphorylation of epidermal growth factor receptor: evidence for a model of intermolecular allosteric activation," <i>Biochemistry</i> (1987), Vol. 26, No. 5, pp. 1434-1442.		
	A11	YANABU ET AL., "Tyrosine phosphorylation and p72syk activation by an anti-glycoprotein Ib monoclonal antibody," <i>Blood</i> (1997), Vol. 89, No. 5, pp. 1590-1598.		

RECEIVED
APR 29 2003

Examiner Signature	<i>Lynn Buehl</i>	Date Considered	1/29/06
--------------------	-------------------	-----------------	---------


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/645,085
				Filing Date	10/07/2002
				First Named Inventor	Naoshi FUKUSHIMA et al.
				Group Art Unit	1653
				Examiner Name	Unassigned
				Attorney Docket Number	065678-0108
Sheet	1	of			

[illegible][illegible]

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
LAB ↓	B3	LINDBERG et al., "Molecular Cloning of Integrin-Associated Protein: An Immunoglobulin Family Member with Multiple Membrane-Spanning Domains Implicated in $\alpha_v\beta_3$ -Dependent Ligand Binding," The Journal of Cell Biology, Vol. 123, No. 2, The Rockefeller University Press, October 1993, pp. 485-496.	
	B4	MATEO et al., "Induction of Apoptosis in B-Cells From Chronic Lymphocytic Leukemia (B-CLLs) by CD47," FASEB Journal, Vol. 12, No. 5, March 20, 1998, pg. A1082.	
	B5	FUKUSHIMA et al., "Apoptosis of Bone Marrow Cells Via Integrin Associated Protein by the Novel Monoclonal Antibody," Blood, Vol. 94, No. 10, November 15, 1999, pg. 479A	

Examiner Signature	<i>Ann B. Smith</i>	Date Considered	1/20/06
-----------------------	---------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.